• October 20th, 2011
• Evotec and APEIRON Biologics start next project on the Cbl-b target
• Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.
  Apeiron Press Release
  Apeiron Presseaussendung
• September 24th, 2011
• Children’s Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma with hu14.18-IL2 (APN301)
• APEIRON Biologics AG and the Children’s Oncology Group today announced to collaborate in a phase II study with Apeiron’s APN301 in pediatric neuroblastoma patients.Neuroblastoma can be one of the most difficult to treat childhood cancers with about 650 to 750 children diagnosed each year in the U.S. and the E.U., respectively.
  Apeiron Press Release
  Apeiron Presseaussendung
• June 22nd, 2011
• Apeiron acquires rights for Phase III immunotherapy against high-risk neuroblastoma from CCRI and SIOPEN
• APEIRON Biologics AG (Apeiron) today announced the signing of agreements with the Children’s Cancer Research Institute, Vienna (CCRI) and the European Neuroblastoma Research Network (SIOPEN) that grant Apeiron the rights to further develop and commercialize the monoclonal antibody ch14.18 together with these groups. This antibody presently is being investigated by CCRI and SIOPEN in a Phase III study in high-risk neuroblastoma patients in many centers in Europe. Production is contracted to Polymun Scientific.
  Apeiron Press Release
  Apeiron Presseaussendung
  PK Fotos
• March 15th, 2011
• Apeiron acquires option to license rights to novel oncology compounds from Cleveland Clinic
• APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system.
  Apeiron Press Release
  Apeiron Presseaussendung
• February 1st, 2011
• Apeiron acquires rights for a phase II biologic against neuroblastoma and other cancers from Merck KGaA, Germany
• APEIRON Biologics AG (Apeiron) today announced the signing of an agreement that will grant Apeiron the rights to further develop and commercialize the investigational immunocytokine hu14.18-IL2 which has recently shown preliminary activity in a subset of children suffering from neuroblastoma in a Phase II clinical study.
  Apeiron Press Release
  Apeiron Presseaussendung
• January 10th, 2011
• Experienced venture capitalist / pharma manager joins Apeiron’s business development team
• APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company's business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities.
  Apeiron Press Release
  Apeiron Presseaussendung
• November 4th, 2010
• Apeiron acquires rights to new clinical stage project
• APEIRON Biologics AG (Apeiron) today announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH (Polymun) granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD) for treatment of various inflammatory conditions
  Apeiron Press Release
  Apeiron Presseaussendung
• October 27th, 2010
• Pain alliance with Evotec
• Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and APEIRON Biologics AG today announced that they have entered into a collaboration to identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms.
  Apeiron Press Release
  Apeiron Presseaussendung
• October 4th, 2010
• European Biotechnica Award 2010
• Apeiron among the three finalists nominated for the EUROPEAN BIOTECHNICA AWARD 2010
  Other finalists are listed companies Addex Pharmaceuticals (Switzerland) and Galapagos Genomics (Belgium)
• April 30th, 2010
• Biotech-Pharma Partnerships
• LISA VR Press Talk: current partnerships between biotech and pharma in Vienna
  LISA VR Press Talk
• February 3rd, 2010
• Exclusive Licence Agreement with GSK
• Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).
  Apeiron_GSK_Press_Release
  Apeiron_GSK_Press_Release_de
• November 17th, 2009
• Manfred Reichl awarded Business Angel of the Year
• On Nov. 17th, one of our major shareholders, business angel and Chairman of the Supervisory Board, DDr. Manfred Reichl has received the award "Business Angel of the Year". Congratulations!
• October 18th, 2009
• Award-winning Gavin Oudit MD
• We congratulate our collaborator Gavin Oudit MD for receiving an award from the Canadian Cardiovascular Society for the "highly innovative and productive research program" he established with Apeiron. "This work opens new, very promising avenues for the treatment of patients with heart failure. The committee has been highly impressed by the translational nature of Oudit's program, from fundamental molecular advances in our understanding of ACE2 biology to clinical applications.
  > more
• August 20th, 2009
• Oncotyrol
• Apeiron announces its participation in "Oncotyrol - Center for Personalized Cancer Medicine", an international partnership between academia and industry providing an excellent framework for the development of Apeiron's Cbl-b project.
• May 8th, 2009
• APN01: First volunteer receives treatment
• Treatment of the first healthy volunteer in a placebo-controlled phase I clinical study with APN01
• January 13th, 2009
• pre-IND meeting with US-FDA
• pre-IND meeting with US-FDA (APN01 in heart failure)
• June 24th, 2008
• APN01
• APN01 GMP-batch for first clinical trials ready
• March 12th, 2008
• pre-IND meeting with US-FDA
• pre-IND meeting with US-FDA (APN01 in ARDS)